Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation.

Pasch CA, Favreau PF, Yueh AE, Babiarz CP, Gillette AA, Sharick JT, Karim MR, Nickel KP, DeZeeuw AK, Sprackling CM, Emmerich PB, DeStefanis RA, Pitera RT, Payne SN, Korkos DP, Clipson L, Walsh CM, Miller D, Carchman EH, Burkard ME, Lemmon KK, Matkowskyj KA, Newton MA, Ong IM, Bassetti MF, Kimple RJ, Skala MC, Deming DA.

Clin Cancer Res. 2019 Jun 7. doi: 10.1158/1078-0432.CCR-18-3590. [Epub ahead of print]

PMID:
31175091
2.

Nucleoside Analogs with Selective Antiviral Activity against Dengue Fever and Japanese Encephalitis Viruses.

Zandi K, Bassit L, Amblard F, Cox BD, Hassandarvish P, Moghaddam E, Yueh A, Libanio Rodrigues GO, Passos I, Costa VV, AbuBakar S, Zhou L, Kohler J, Teixeira MM, Schinazi RF.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00397-19. doi: 10.1128/AAC.00397-19. Print 2019 Jul.

PMID:
31061163
3.

A novel, potent, and orally bioavailable thiazole HCV NS5A inhibitor for the treatment of hepatitis C virus.

Yeh TK, Kang IJ, Hsu TA, Lee YC, Lee CC, Hsu SJ, Tian YW, Yang HY, Chen CT, Chao YS, Yueh A, Chern JH.

Eur J Med Chem. 2019 Apr 1;167:245-268. doi: 10.1016/j.ejmech.2019.02.016. Epub 2019 Feb 6.

PMID:
30772607
4.
5.

MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers.

Fricke SL, Payne SN, Favreau PF, Kratz JD, Pasch CA, Foley TM, Yueh AE, Van De Hey DR, Depke MG, Korkos DP, Sha GC, DeStefanis RA, Clipson L, Burkard ME, Lemmon KK, Parsons BM, Kenny PA, Matkowskyj KA, Newton MA, Skala MC, Deming DA.

Mol Cancer Ther. 2019 Feb;18(2):346-355. doi: 10.1158/1535-7163.MCT-18-0510. Epub 2018 Nov 13.

PMID:
30425131
6.

The conserved stem-loop II structure at the 3' untranslated region of Japanese encephalitis virus genome is required for the formation of subgenomic flaviviral RNA.

Chen YS, Fan YH, Tien CF, Yueh A, Chang RY.

PLoS One. 2018 Jul 26;13(7):e0201250. doi: 10.1371/journal.pone.0201250. eCollection 2018.

7.

Development of robust genotype 1a hepatitis C replicons harboring adaptive mutations for facilitating the antiviral drug discovery and study of virus replication.

Lin HM, Wu PS, Hu HS, Chang WC, Wu RH, Tian JN, Chern JH, Yueh A.

J Virol Methods. 2018 Sep;259:10-17. doi: 10.1016/j.jviromet.2018.05.010. Epub 2018 May 18.

PMID:
29782889
8.

Mutagenesis of Dengue Virus Protein NS2A Revealed a Novel Domain Responsible for Virus-Induced Cytopathic Effect and Interactions between NS2A and NS2B Transmembrane Segments.

Wu RH, Tsai MH, Tsai KN, Tian JN, Wu JS, Wu SY, Chern JH, Chen CH, Yueh A.

J Virol. 2017 May 26;91(12). pii: e01836-16. doi: 10.1128/JVI.01836-16. Print 2017 Jun 15.

9.

Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA Mutations.

Foley TM, Payne SN, Pasch CA, Yueh AE, Van De Hey DR, Korkos DP, Clipson L, Maher ME, Matkowskyj KA, Newton MA, Deming DA.

Mol Cancer Res. 2017 Feb 9;15(3):317-327. doi: 10.1158/1541-7786.MCR-16-0256. [Epub ahead of print]

10.

A Potent, Selective, and Orally Bioavailable HCV NS5A Inhibitor for Treatment of Hepatitis C Virus: (S)-1-((R)-2-(Cyclopropanecarboxamido)-2-phenylacetyl)-N-(4-phenylthiazol-2-yl)pyrrolidine-2-carboxamide.

Kang IJ, Hsu SJ, Yang HY, Yeh TK, Lee CC, Lee YC, Tian YW, Song JS, Hsu TA, Chao YS, Yueh A, Chern JH.

J Med Chem. 2017 Jan 12;60(1):228-247. doi: 10.1021/acs.jmedchem.6b00962. Epub 2016 Dec 28.

PMID:
27966956
11.

Colon Cancer Tumorigenesis Initiated by the H1047R Mutant PI3K.

Yueh AE, Payne SN, Leystra AA, Van De Hey DR, Foley TM, Pasch CA, Clipson L, Matkowskyj KA, Deming DA.

PLoS One. 2016 Feb 10;11(2):e0148730. doi: 10.1371/journal.pone.0148730. eCollection 2016.

12.

PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors.

Payne SN, Maher ME, Tran NH, Van De Hey DR, Foley TM, Yueh AE, Leystra AA, Pasch CA, Jeffrey JJ, Clipson L, Matkowskyj KA, Deming DA.

Oncogenesis. 2015 Oct 5;4:e169. doi: 10.1038/oncsis.2015.28.

13.

Identification of Substituted Naphthotriazolediones as Novel Tryptophan 2,3-Dioxygenase (TDO) Inhibitors through Structure-Based Virtual Screening.

Wu JS, Lin SY, Liao FY, Hsiao WC, Lee LC, Peng YH, Hsieh CL, Wu MH, Song JS, Yueh A, Chen CH, Yeh SH, Liu CY, Lin SY, Yeh TK, Hsu JT, Shih C, Ueng SH, Hung MS, Wu SY.

J Med Chem. 2015 Oct 8;58(19):7807-19. doi: 10.1021/acs.jmedchem.5b00921. Epub 2015 Sep 16.

PMID:
26348881
14.

Colon Tumors with the Simultaneous Induction of Driver Mutations in APC, KRAS, and PIK3CA Still Progress through the Adenoma-to-carcinoma Sequence.

Hadac JN, Leystra AA, Paul Olson TJ, Maher ME, Payne SN, Yueh AE, Schwartz AR, Albrecht DM, Clipson L, Pasch CA, Matkowskyj KA, Halberg RB, Deming DA.

Cancer Prev Res (Phila). 2015 Oct;8(10):952-61. doi: 10.1158/1940-6207.CAPR-15-0003. Epub 2015 Aug 14.

16.

Baicalin, a metabolite of baicalein with antiviral activity against dengue virus.

Moghaddam E, Teoh BT, Sam SS, Lani R, Hassandarvish P, Chik Z, Yueh A, Abubakar S, Zandi K.

Sci Rep. 2014 Jun 26;4:5452. doi: 10.1038/srep05452.

17.

A novel approach to propagate flavivirus infectious cDNA clones in bacteria by introducing tandem repeat sequences upstream of virus genome.

Pu SY, Wu RH, Tsai MH, Yang CC, Chang CM, Yueh A.

J Gen Virol. 2014 Jul;95(Pt 7):1493-503. doi: 10.1099/vir.0.064915-0. Epub 2014 Apr 11.

PMID:
24728712
18.

A novel dengue virus inhibitor, BP13944, discovered by high-throughput screening with dengue virus replicon cells selects for resistance in the viral NS2B/NS3 protease.

Yang CC, Hu HS, Wu RH, Wu SH, Lee SJ, Jiaang WT, Chern JH, Huang ZS, Wu HN, Chang CM, Yueh A.

Antimicrob Agents Chemother. 2014;58(1):110-9. doi: 10.1128/AAC.01281-13. Epub 2013 Oct 21.

19.

Protein release from dihydroxyacetone-based poly(carbonate ester) matrices.

Weiser JR, Yueh A, Putnam D.

Acta Biomater. 2013 Sep;9(9):8245-53. doi: 10.1016/j.actbio.2013.05.020. Epub 2013 Jun 7.

PMID:
23747318
20.

Characterization of an efficient dengue virus replicon for development of assays of discovery of small molecules against dengue virus.

Yang CC, Tsai MH, Hu HS, Pu SY, Wu RH, Wu SH, Lin HM, Song JS, Chao YS, Yueh A.

Antiviral Res. 2013 May;98(2):228-41. doi: 10.1016/j.antiviral.2013.03.001. Epub 2013 Mar 13.

PMID:
23499649
21.

Resistance studies of a dithiazol analogue, DBPR110, as a potential hepatitis C virus NS5A inhibitor in replicon systems.

Lin HM, Wang JC, Hu HS, Wu PS, Wang WH, Wu SY, Yang CC, Yeh TK, Hsu TA, Jiaang WT, Chao YS, Chern JH, Yueh A.

Antimicrob Agents Chemother. 2013 Feb;57(2):723-33. doi: 10.1128/AAC.01403-12. Epub 2012 Nov 19.

22.

A mechanistic analysis of the quantitation of α-hydroxy ketones by the bicinchoninic acid assay.

Weiser JR, Ricapito NG, Yueh A, Weiser EL, Putnam D.

Anal Biochem. 2012 Nov 15;430(2):116-22. doi: 10.1016/j.ab.2012.08.009. Epub 2012 Aug 19.

PMID:
22910661
23.

Large ribosomal protein 4 increases efficiency of viral recoding sequences.

Green L, Houck-Loomis B, Yueh A, Goff SP.

J Virol. 2012 Sep;86(17):8949-58. doi: 10.1128/JVI.01053-12. Epub 2012 Jun 20.

24.

Resistance analysis and characterization of a thiazole analogue, BP008, as a potent hepatitis C virus NS5A inhibitor.

Lin HM, Wang JC, Hu HS, Wu PS, Yang CC, Wu CP, Pu SY, Hsu TA, Jiaang WT, Chao YS, Chern JH, Yeh TK, Yueh A.

Antimicrob Agents Chemother. 2012 Jan;56(1):44-53. doi: 10.1128/AAC.00599-11. Epub 2011 Oct 17.

25.

Isatin-β-thiosemicarbazones as potent herpes simplex virus inhibitors.

Kang IJ, Wang LW, Hsu TA, Yueh A, Lee CC, Lee YC, Lee CY, Chao YS, Shih SR, Chern JH.

Bioorg Med Chem Lett. 2011 Apr 1;21(7):1948-52. doi: 10.1016/j.bmcl.2011.02.037. Epub 2011 Feb 15.

PMID:
21356589
26.

Successful propagation of flavivirus infectious cDNAs by a novel method to reduce the cryptic bacterial promoter activity of virus genomes.

Pu SY, Wu RH, Yang CC, Jao TM, Tsai MH, Wang JC, Lin HM, Chao YS, Yueh A.

J Virol. 2011 Mar;85(6):2927-41. doi: 10.1128/JVI.01986-10. Epub 2011 Jan 12.

27.

Novel dengue virus-specific NS2B/NS3 protease inhibitor, BP2109, discovered by a high-throughput screening assay.

Yang CC, Hsieh YC, Lee SJ, Wu SH, Liao CL, Tsao CH, Chao YS, Chern JH, Wu CP, Yueh A.

Antimicrob Agents Chemother. 2011 Jan;55(1):229-38. doi: 10.1128/AAC.00855-10. Epub 2010 Oct 11.

28.

Synthesis, activity, and pharmacokinetic properties of a series of conformationally-restricted thiourea analogs as novel hepatitis C virus inhibitors.

Kang IJ, Wang LW, Yeh TK, Lee CC, Lee YC, Hsu SJ, Wu YS, Wang JC, Chao YS, Yueh A, Chern JH.

Bioorg Med Chem. 2010 Sep 1;18(17):6414-21. doi: 10.1016/j.bmc.2010.07.002. Epub 2010 Jul 8.

PMID:
20675142
29.

Design and efficient synthesis of novel arylthiourea derivatives as potent hepatitis C virus inhibitors.

Kang IJ, Wang LW, Hsu SJ, Lee CC, Lee YC, Wu YS, Yueh A, Wang JC, Hsu TA, Chao YS, Chern JH.

Bioorg Med Chem Lett. 2009 Nov 1;19(21):6063-8. doi: 10.1016/j.bmcl.2009.09.037. Epub 2009 Sep 17.

PMID:
19796940
30.

Design and synthesis of indole, 2,3-dihydro-indole, and 3,4-dihydro-2H-quinoline-1-carbothioic acid amide derivatives as novel HCV inhibitors.

Kang IJ, Wang LW, Hsu SJ, Lee CC, Lee YC, Wu YS, Hsu TA, Yueh A, Chao YS, Chern JH.

Bioorg Med Chem Lett. 2009 Aug 1;19(15):4134-8. doi: 10.1016/j.bmcl.2009.06.009. Epub 2009 Jun 6.

PMID:
19539472
31.

A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity.

Leng CH, Liu SJ, Tsai JP, Li YS, Chen MY, Liu HH, Lien SP, Yueh A, Hsiao KN, Lai LW, Liu FC, Chong P, Chen HW.

Microbes Infect. 2009 Feb;11(2):288-95. doi: 10.1016/j.micinf.2008.12.004. Epub 2008 Dec 16.

PMID:
19114121
32.

Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities.

Lu IL, Huang CF, Peng YH, Lin YT, Hsieh HP, Chen CT, Lien TW, Lee HJ, Mahindroo N, Prakash E, Yueh A, Chen HY, Goparaju CM, Chen X, Liao CC, Chao YS, Hsu JT, Wu SY.

J Med Chem. 2006 May 4;49(9):2703-12.

PMID:
16640330
33.

Interaction of Moloney murine leukemia virus matrix protein with IQGAP.

Leung J, Yueh A, Appah FS Jr, Yuan B, de los Santos K, Goff SP.

EMBO J. 2006 May 17;25(10):2155-66. Epub 2006 Apr 20.

34.

Interaction of moloney murine leukemia virus capsid with Ubc9 and PIASy mediates SUMO-1 addition required early in infection.

Yueh A, Leung J, Bhattacharyya S, Perrone LA, de los Santos K, Pu SY, Goff SP.

J Virol. 2006 Jan;80(1):342-52.

37.
38.
39.
40.

The carboxyl-terminal transactivation domain of human serum response factor contains DNA-activated protein kinase phosphorylation sites.

Liu SH, Ma JT, Yueh AY, Lees-Miller SP, Anderson CW, Ng SY.

J Biol Chem. 1993 Oct 5;268(28):21147-54.

41.

Supplemental Content

Support Center